CR

Carlo Rizzuto

Managing Director at Versant Ventures

New York, New York

Overview 

Carlo Rizzuto is a Managing Director at Versant Ventures in New York, overseeing investments in pharmaceutical and biotech companies. With a background in strategic planning, business development, and cross-functional team leadership, Rizzuto has invested in successful companies like Nexo Therapeutics and Graphite Bio, contributing to their growth and development. Rizzuto's career highlights include serving as CEO of Highline Therapeutics and holding leadership roles at Novartis, where he was involved in global program management and business strategy. His expertise in venture capital, drug development, and life sciences has been instrumental in guiding innovative startups to success.

Work Experience 

VV

Versant Ventures

  • Managing Director

    2022 - Current

  • Partner

    2012 - 2022

    Director, Graphite Bio (GRPH) Director, Century Therapeutics (IPSC) Director, Jnana Therapeutics Director, FirstLight Bio Director, 858 Therapeutics Director, Stablix Director, Nested Therapeutics Director, Pandion Therapeutics (PAND, acquired) Director, Venatorx (2017-2022) Founding CEO, Kyras Therapeutics (2015-2017) Chief Business Officer, Anokion (2014-2017)

Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.

versantventures.com

Highline Therapeutics

  • CEO

    2015 - 2022

    Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.

N

Novartis

  • Global Program Team Director

    2010 - 2012

    Lead global, cross-functional team developing intelligent medicines by integrating electronics and pharmaceuticals to enable remote patient monitoring/e-health applications

Novartis International AG

  • Assistant to the CEO

    2010 - 2010

N

Novartis

  • Assistant to CEO - Pharmaceuticals

    2009 - 2010

M&

McKinsey & Company

  • Associate Principal

    2002 - 2008

McKinsey Growth Tech serves leading growth stage tech players, venture capital, and growth private equity

mckinsey.com

engeneOS

  • Business Development Manager

    2000 - 2002

Education 

Investments 

Nexo Therapeutics

Series A

Total funding: $60M

Jnana Therapeutics

Series A

Total funding: $160M

Nested Therapeutics

Seed

Total funding: $35M

Stablix

Series A

Total funding: $63M

Articles About Carlo

Relevant Websites